Status:
COMPLETED
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile invol...
Eligibility Criteria
Inclusion
- histologically or cytologically proven diagnosis of non-small cell lung cancer
- positive for the ALK fusion gene (test provided by a central laboratory)
- must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug
- tumors must be measurable
Exclusion
- prior treatment with PF-02341066
- current treatment in another clinical trial
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
347 Patients enrolled
Trial Details
Trial ID
NCT00932893
Start Date
September 1 2009
End Date
January 1 2016
Last Update
January 2 2017
Active Locations (264)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas for Medical Research, Winthrop Rockefeller Cancer Institute
Little Rock, Arkansas, United States, 72205
2
Comprehensive Blood and Cancer Center
Bakersfield, California, United States, 93309
3
Tower Cancer Research Foundation
Beverly Hills, California, United States, 90211-1850
4
Tower Hematology Oncology Medical Group
Beverly Hills, California, United States, 90211